Phenylketonuria ( PKU) - Dr Padmesh

28
DEFECTS IN METABOLISM OF AMINO ACIDS : PHENYLKETONURIA (PKU) Dr.Padmesh. V

Transcript of Phenylketonuria ( PKU) - Dr Padmesh

Page 1: Phenylketonuria ( PKU)  - Dr Padmesh

DEFECTS IN METABOLISM OF AMINO ACIDS :

PHENYLKETONURIA (PKU)

Dr.Padmesh. V

Page 2: Phenylketonuria ( PKU)  - Dr Padmesh

Phenylalanine is an essential amino acid.

Dietary phenylalanine not utilized for protein synthesis is normally degraded by way of the Tyrosine pathway.

Deficiency of the enzyme phenylalanine hydroxylase(PAH) or of its cofactor tetrahydrobiopterin (BH4)

Accumulation of phenylalanine in body fluids & brain.

Page 3: Phenylketonuria ( PKU)  - Dr Padmesh

The severity of hyperphenylalaninemia depends on the degree of enzyme deficiency .

May vary from very high plasma concentrations

( >20 mg/dL, classic phenylketonuria [PKU] ) to

mildly elevated levels, hyperphenylalaninemia

(2-6 mg/dL).

Page 4: Phenylketonuria ( PKU)  - Dr Padmesh

In affected infants with plasma concentrations >20 mg/dL

Excess phenylalanine is metabolized to Phenylketones

(Phenylpyruvate and Phenylacetate)

Excreted in the urine

(giving rise to the term phenylketonuria (PKU))

Page 5: Phenylketonuria ( PKU)  - Dr Padmesh

The brain is the main organ affected by hyperphenylalaninemia.

The CNS damage in affected patients is caused by the elevated concentration of phenylalanine in brain tissue.

The high blood levels of phenylalanine in PKU saturate the transport system across the blood-brain barrier causing inhibition of the cerebral uptake of other large neutral amino acids such as tyrosine and tryptophan.

Page 6: Phenylketonuria ( PKU)  - Dr Padmesh

All defects causing hyperphenylalaninemia are inherited as autosomal recessive traits.

Prenatal diagnosis is possible using specific genetic probes in cells obtained from chorionic villi biopsy.

Page 7: Phenylketonuria ( PKU)  - Dr Padmesh

Classic Phenylketonuria

(Plasma phenylalanine levels >20 mg/dL)

Page 8: Phenylketonuria ( PKU)  - Dr Padmesh

Clinical Manifestations

The affected infant is normal at birth.

Profound mental retardation develops gradually if the infant remains untreated.

Cognitive delay may not be evident for the 1st few months.

In untreated patients, 50-70% will have an IQ below 35, and 88-90% below 65.

Only 2-5% of untreated patients will have normal intelligence.

Page 9: Phenylketonuria ( PKU)  - Dr Padmesh

Clinical Manifestations

Vomiting, sometimes severe enough to be misdiagnosed as pyloric stenosis, may be an early symptom.

Older untreated children become hyperactive with autistic behaviors, including purposeless hand movements, rhythmic rocking, and athetosis.

Page 10: Phenylketonuria ( PKU)  - Dr Padmesh

Clinical Manifestations

The infants are lighter in their complexion than unaffected siblings.

Some may have a seborrheic or eczematoid rash,(mild and disappears as the child grows older).

These children have an unpleasant MUSTY or MOUSEY odour of phenylacetic acid.

Page 11: Phenylketonuria ( PKU)  - Dr Padmesh

Clinical Manifestations

Neurologic signs : Seizures (≈25%), spasticity, hyperreflexia, and tremors.

More than 50% have EEG abnormalities.

Microcephaly, prominent maxillae with widely spaced teeth, enamel hypoplasia, and growth retardation.

Page 12: Phenylketonuria ( PKU)  - Dr Padmesh

Milder Forms of

Hyperphenylalaninemia /

Non-PKU Hyperphenylalaninemias

(Plasma phenylalanine levels >2 mg/dL,

but <20 mg/dL)

Page 13: Phenylketonuria ( PKU)  - Dr Padmesh

These infants do not excrete phenylketones.

But may still require dietary interventions.

Possibility of deficiency of BH4 should be investigated in all infants with the milder forms of hyperphenylalaninemia.

Page 14: Phenylketonuria ( PKU)  - Dr Padmesh

Diagnosis :

Usually diagnosed through Newborn screening.

If screening is positive diagnosis should be confirmed by quantitative measurement of plasma phenylalanine concentration.

Identification and measurement of phenylketones in the urine has no place in any screening program.

In countries where such programs are not in effect, identification of phenylketones in the urine by ferric chloride may offer a simple test for diagnosis of infants with developmental and neurologic abnormalities.

Page 15: Phenylketonuria ( PKU)  - Dr Padmesh

Diagnosis :

Once hyperphenylalaninemia is diagnosed, additional studies for biopterin metabolism should be performed to rule out biopterin deficiency as the cause of hyperphenylalaninemia.

Page 16: Phenylketonuria ( PKU)  - Dr Padmesh

Neonatal Screening for Hyperphenylalaninemia :

The method of choice is Tandem mass spectrometry (MS/MS), which identifies all forms of hyperphenyalaninemia with a low false-positive rate, and excellent accuracy and precision.

The addition of the phenylalanine/tyrosine molar ratio has further reduced the number of false-positive results.

Diagnosis must be confirmed by measurement of plasma phenylalanine concentration.

Page 17: Phenylketonuria ( PKU)  - Dr Padmesh

Blood phenylalanine in affected infants with PKU may rise to diagnostic levels as early as 4 hr after birth even in the absence of protein feeding.

It is recommended that the blood for screening be obtained in the FIRST 24-48 hr of life after feeding protein to reduce the possibility of false-negative results, especially in the milder forms of the condition.

Page 18: Phenylketonuria ( PKU)  - Dr Padmesh

Treatment

Goal of therapy: To reduce phenylalanine levels in plasma & brain.

Infants with persistent (more than a few days) plasma levels of phenylalanine >6 mg/dL should be treated with a phenylalanine-restricted diet similar to that for classic PKU.

Formulas low in or free of phenylalanine.

The diet should be started as soon as diagnosis is established.

Page 19: Phenylketonuria ( PKU)  - Dr Padmesh

Treatment

Because phenylalanine is not synthesized endogenously, small amounts of phenylalanine should be added to the diet to prevent phenylalanine deficiency.

Dietary deficiency of phenylalanine is manifested by lethargy, failure to thrive, anorexia, anemia, rashes, diarrhea, and even death.

Tyrosine becomes an essential amino acid in this disorder and its adequate intake must be ensured.

Page 20: Phenylketonuria ( PKU)  - Dr Padmesh

Treatment

Plasma phenylalanine levels to be maintained:

In neonates through 12 yr of age: Between 2 - 6 mg/dL

In older individuals: Between 2 - 10 mg/dL

Discontinuation of therapy, even in adulthood, may cause deterioration of IQ and cognitive performance Therefore phenylalanine-restricted diet should be continued for life.

Page 21: Phenylketonuria ( PKU)  - Dr Padmesh

Treatment

Oral administration of Tetrahydrobiopterin (BH4) may result in reduction of plasma levels of phenylalanine in some patients with PAH deficiency.

Sapropterin, a synthetic form of BH4 is approved by the Food and Drug Administration (FDA) to reduce phenylalanine levels in PKU.

At a dose of 10 mg/kg/day, it reduces phenylalanine levels in up to 50% of patients.

Page 22: Phenylketonuria ( PKU)  - Dr Padmesh

Hyperphenylalaninemia

due to Deficiency of

the Cofactor BH4

Page 23: Phenylketonuria ( PKU)  - Dr Padmesh

In 1-3% of infants with hyperphenylalaninemia, the defect resides in 1 of the enzymes necessary for production or recycling of the cofactor BH4.

If these infants are misdiagnosed as having PKU, they may deteriorate neurologically despite adequate control of plasma phenylalanine.

In addition to acting as a cofactor for PAH, BH4 is also a cofactor for tyrosine hydroxylase and tryptophan hydroxylase, which are involved in the biosynthesis of dopamine and serotonin.

Therefore, patients with hyperphenylalaninemia due to BH4

deficiency also manifest neurologic findings related to deficiencies of the neurotransmitters dopamine and serotonin.

Page 24: Phenylketonuria ( PKU)  - Dr Padmesh

Clinical Manifestations

Clinical manifestations of the neurotransmitter disorders differ greatly from those of PKU.

Neurologic symptoms of the neurotransmitter disorders often manifest in the 1st few months of life.

Include extrapyramidal signs with choreoathetotic or dystonic limb movements, axial and truncal hypotonia, hypokinesia, feeding difficulties, and autonomic problems.

Mental retardation, seizures, hypersalivation, and swallowing difficulties are also seen.

The symptoms are usually progressive and often have a marked diurnal fluctuation.

Page 25: Phenylketonuria ( PKU)  - Dr Padmesh

Diagnosis

1. Measurement of neopterin and biopterin in body

fluids, especially urine.

In addition, examination of cerebrospinal fluid (CSF) reveals decreased levels of dopamine, serotonin, and their metabolites in all patients with BH4 deficiency.

2. BH4 loading test;

3. Enzyme assay: The activity of dihydropteridinereductase can be measured in the dry blood spots on the filter paper used for screening purposes.

Page 26: Phenylketonuria ( PKU)  - Dr Padmesh

Treatment The goals of therapy are:

To correct hyperphenylalaninemia, and

To restore neurotransmitter deficiencies in the CNS.

Plasma phenylalanine should be maintained as close to normal as possible (<6 mg/dL).

This can be achieved by a combination of a low phenylalanine diet and oral supplementation of BH4.

Infants with GTP cyclohydrolase or 6-PTS deficiencies respond more readily to BH4 therapy (5-10 mg/kg/day) than those with dihydropteridine reductase deficiency. In the latter patients, doses as high as 20 mg/kg/day may be required.

Page 27: Phenylketonuria ( PKU)  - Dr Padmesh

Treatment

Lifelong supplementation with neurotransmitter precursors such as L-dopa and 5-hydroxytryptophan, along with carbidopa.

Supplementation with folinic acid in patients with dihydropteridine reductase deficiency.

Some drugs such as trimethoprim-sulfamethoxazole, methotrexate, and other antileukemic agents are known to inhibit dihydropteridine reductase enzyme activity and should be used with great caution in patients with BH4

deficiency.

Page 28: Phenylketonuria ( PKU)  - Dr Padmesh

www.slideshare.net/Dr_Padmeshdnbpediatricstheory.blogspot.com/oscepediatrics.blogspot.com/